Bispecific T-cell engagers are a
new class of immunotherapeutics with efficacy in hematologic and solid
malignancies. These agents share similar toxicities with other T-cell
engaging therapies, including cytokine release syndrome and immune
effector cell-associated neurotoxicity. With ever-increasing utilization
of bispecific T-cell engagers, seeking collaboration across care
settings – from community-based/rural clinical practices to academic
medical centers – will be key. Optimization of bispecific T-cell engager
administration requires a proactive approach across these teams to
address transitions of care, prevention and management of reactions and
other toxicities (including fine-tuning premedications), education of
medical staff, financial and operational challenges (such as formulary
management), and patient selection. This session aims to review updates
associated with and provide tools to implement best practices for these
considerations.